ProKidney Reconciled Depreciation from 2010 to 2025

PROK Stock  USD 0.90  0.04  4.26%   
ProKidney Corp Reconciled Depreciation yearly trend continues to be quite stable with very little volatility. The value of Reconciled Depreciation is projected to decrease to about 3.3 M. From the period between 2010 and 2025, ProKidney Corp, Reconciled Depreciation regression line of its data series had standard deviation of  1,353,008 and standard deviation of  1,353,008. View All Fundamentals
 
Reconciled Depreciation  
First Reported
2010-12-31
Previous Quarter
5.4 M
Current Value
3.3 M
Quarterly Volatility
1.4 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check ProKidney Corp financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ProKidney Corp's main balance sheet or income statement drivers, such as Depreciation And Amortization of 3 M, Interest Expense of 8.6 K or Selling General Administrative of 34.8 M, as well as many indicators such as Price To Sales Ratio of 2.2 K, Dividend Yield of 0.0 or Days Sales Outstanding of 9.4 K. ProKidney financial statements analysis is a perfect complement when working with ProKidney Corp Valuation or Volatility modules.
  
Check out the analysis of ProKidney Corp Correlation against competitors.
For more information on how to buy ProKidney Stock please use our How to buy in ProKidney Stock guide.

Latest ProKidney Corp's Reconciled Depreciation Growth Pattern

Below is the plot of the Reconciled Depreciation of ProKidney Corp over the last few years. It is ProKidney Corp's Reconciled Depreciation historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in ProKidney Corp's overall financial position and show how it may be relating to other accounts over time.
Reconciled Depreciation10 Years Trend
Slightly volatile
   Reconciled Depreciation   
       Timeline  

ProKidney Reconciled Depreciation Regression Statistics

Arithmetic Mean1,739,692
Geometric Mean1,412,433
Coefficient Of Variation77.77
Mean Deviation1,066,577
Median964,000
Standard Deviation1,353,008
Sample Variance1.8T
Range4.5M
R-Value0.76
Mean Square Error834.1B
R-Squared0.57
Significance0.0007
Slope215,444
Total Sum of Squares27.5T

ProKidney Reconciled Depreciation History

20253.3 M
20245.4 M
20233.5 M
2022M
2021M

About ProKidney Corp Financial Statements

ProKidney Corp investors utilize fundamental indicators, such as Reconciled Depreciation, to predict how ProKidney Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Reconciled Depreciation5.4 M3.3 M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether ProKidney Corp is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if ProKidney Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Prokidney Corp Stock. Highlighted below are key reports to facilitate an investment decision about Prokidney Corp Stock:
Check out the analysis of ProKidney Corp Correlation against competitors.
For more information on how to buy ProKidney Stock please use our How to buy in ProKidney Stock guide.
You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ProKidney Corp. If investors know ProKidney will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ProKidney Corp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.62)
Revenue Per Share
0.001
Return On Assets
(0.26)
Return On Equity
(0.41)
The market value of ProKidney Corp is measured differently than its book value, which is the value of ProKidney that is recorded on the company's balance sheet. Investors also form their own opinion of ProKidney Corp's value that differs from its market value or its book value, called intrinsic value, which is ProKidney Corp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ProKidney Corp's market value can be influenced by many factors that don't directly affect ProKidney Corp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ProKidney Corp's value and its price as these two are different measures arrived at by different means. Investors typically determine if ProKidney Corp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ProKidney Corp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.